FDA OKs GE HealthCare’s Photonova Spectra Photon-Counting CT System

GE HealthCare has earned U.S. Food and Drug Administration (FDA) clearance for Photonova Spectra, a photon-counting CT (PCCT) powered by the company’s Deep Silicon detector technology.

Photonova Spectra is offered as a flexible platform with multiple configurations. It features wide coverage and the combo of ultra-high definition spatial and spectral imaging to enable fast acquisition speeds and precise visualization of subtle tissue variations, small lesions, and vascular structures, the company said.

Photon-counting CT directly county individual photons and measures their energy. The approach allows higher spectral and spatial resolution as well as improved tissue characterization.

“As clinicians across the United States face rising volumes and increasing diagnostic complexity, technology must do more than capture images; it must simplify decision-making and strengthen performance across the enterprise,” said Catherine Estrampes, president & CEO, U.S. and Canada, GE HealthCare. “Photonova Spectra is designed to deliver rich clinical insights in every scan and help alleviate cognitive burden for care teams. With the U.S. 510(k) clearance, we are proud to now bring this innovation to U.S. healthcare systems and the patients they serve.”

The Deep Silicon tech, a high-performing semiconductor material, enables precise measurement of photon energy and delivers high levels of energy resolution. This way, clinicians can obtain spectral images with high levels of contrast and deep visualization across neurological, oncological, musculoskeletal, thoracic, and cardiac imaging.

Deep Silicon with 8-bin energy resolution also supports advanced material separation and characterization capabilities. This enables Photonova Spectra to distinguish between materials like iodine, calcium, and fat with precision. A wide detector coverage and 0.23 second rotation speed also support fast imaging and motion-free imaging.

The PCCT incorporates NVIDIA accelerated computing technology, which is designed to handle up to 50 times more data than conventional CT. The GPU-powered architecture was designed to maintain smooth, efficient workflows and CUDA-optimized reconstruction to turn massive spectral datasets into timely, clinically actionable images.

A one-scan, universal full-fidelity approach aims to reduce exam-specific protocols and allow automated reconstruction of ultra-high definition spectral images on demand. The CT ONE operator environment and Auto Positioning feature were designed to improve consistency and simplify the CT process, as well.

“Photonova Spectra reflects years of intentional design and close collaboration with clinicians, researchers and collaborators across the globe,” adds Jean-Luc Procaccini, president and CEO of Molecular Imaging and Computed Tomography, GE HealthCare. “From the earliest stages to today, we remain focused on building a system that addresses the practical realities of clinical practice while opening pathways for scientific advancement. The result is a photon-counting platform engineered for the needs of today’s care teams, as well as the imaging challenges and research opportunities that will shape the future of CT.”

Last week, the company said it completed the acquisition of Intelerad, a medical imaging software provider for the healthcare industry, for a base price of $2.3 billion.